



## Detection of potential effects of orphenadrine upon anesthesia with propofol and/or thiopental in mice

Y.M. Albadrany<sup>1</sup>, A.S. Naser<sup>1</sup> and K.A. Shaaban<sup>1</sup>

Department of Physiology, Biochemistry and Pharmacology, College of Veterinary Medicine, University of Mosul, Mosul, Iraq

### Article information

#### Article history:

Received 18 July, 2023

Accepted 27 October, 2023

Available online 29 December, 2023

#### Keywords:

Orphenadrine

Propofol

Thiopental

Anesthesia indices

Mice

#### Correspondence:

Y.M. Albadrany

[yasseralbadrany@yahoo.com](mailto:yasseralbadrany@yahoo.com)

### Abstract

Orphenadrine is an anticholinergic drug used in clinics as a muscle relaxant. It acts on several receptors, including muscarinic, histaminic, and NMDA. This study aimed to evaluate the effect of pretreatment with orphenadrine on the anesthesia indices of two essential parenteral anesthetic drugs in mice. Three experiments were performed with 15 mice per experiment. All experiments used orphenadrine at 10 mg and 20 mg/kg/IP b.wt as a pretreatment drug. Propofol (100 mg/kg/IP), thiopental (50 mg/kg/IP), and their combinations were used in the first, second, and third experiments, respectively. The indices of anesthesia, represented by the latency to onset of anesthesia, duration of anesthesia, and recovery from anesthesia, were recorded. Orphenadrine at doses of 10 mg and 20 mg/kg/IP as a pretreatment drug showed a dose-dependent decrease in the latency to the onset of anesthesia and an increase in the duration of anesthesia compared to the control groups of all three experiments (propofol 100 mg/kg, thiopental 50 mg/kg, and combinations of propofol and thiopental) respectively. We conclude that orphenadrine affects anesthesia indices, which are recorded for the first time, laying the foundation for further studies and the possibility of using it as an anesthesia co-treatment.

DOI: [10.33899/ijvs.2023.141780.3135](https://doi.org/10.33899/ijvs.2023.141780.3135), ©Authors, 2024, College of Veterinary Medicine, University of Mosul.

This is an open access article under the CC BY 4.0 license (<http://creativecommons.org/licenses/by/4.0/>).

### Introduction

With the advancement of technology, intravenous anesthesia is progressively being introduced into clinical practice, and it is distinguished by faster effects and fewer adverse effects when compared to inhalation anesthetics (1). The specific mechanism of anesthetic achievement is not entirely known; the anesthetic deed can be caused via increasing inhibitory neurotransmitters, decreasing excitatory neurotransmitters, or both (2). Currently, available intravenous anesthetics do not meet the criteria for ideal anesthetic agents because they do not produce all five wanted properties: unconsciousness, amnesia, analgesia, autonomic reflex inhibition, and skeletal muscle relaxation (3). In order to reduce side effects, balanced anesthesia typically uses a combination of medicines, including inhaled anesthetics, sedatives, hypnotics, opioids, and neuromuscular blocking

agents (4). Propofol is a frequently used intravenous anesthetic in the clinical setting. Propofol is a short-acting anesthetic that allows quick and painless recovery (5). Propofol is used for procedures that require quick recovery to preoperative mental capacity (6). Owing to its widespread use, it is now preferred over thiopental for the induction of general anesthesia and sedation (7). Thiopental induces anesthesia; it is given intravenously. Thiopental has a very rapid beginning of action and a high level of lipid solubility (8). The reason for its brief duration of action is that it is also rapidly transferred from the brain to other tissues (muscle and fat). It is utilized for quick surgical procedures and anesthetic induction (9). Orphenadrine is an anticholinergic drug used in Parkinson's disease treatment to decrease some of the most bothersome symptoms, particularly involuntary resting tremors (10). It is used in clinics as a muscle relaxant (11). Orphenadrine acts on several receptors, including

muscarinic, histamine, and NMDA (12). It is also used as an analgesic, even though its particular mode of action is unknown (13).

This study aimed to evaluate the effects of two doses of orphenadrine on propofol and thiopental anesthesia indices. We anticipated that these combinations would lead to secure anesthetic protocols with prompt induction of anesthesia.

## **Materials and methods**

### **Ethical approval**

The animals handling ethics protocol of the College of Veterinary Medicine, University of Mosul, was followed. The Scientific Board of Physiology, Biochemistry, and Pharmacology department approved this study (Ref: UM.VET. 2023. 007, date: 25/3/2023).

### **Animals**

Adult male albino mice (10-12 weeks old, 20-30 g) were used in the study. Five mice were housed per cage in a room kept at  $25\pm 1^\circ\text{C}$  with a relative humidity of  $55\pm 5\%$  and an alternate 12-hour light and dark sequence, with free access to food and water. The animals were used only once in all experiments. The animals were separated and housed in different cages after the IP injection. The experimenters observed the reactions of the mice during the experiments that had been followed from 8 a.m. to 2 p.m.

### **Impact of orphenadrine on the anesthesia induced by propofol in mice**

Fifteen mice were randomized into three equal groups. Group 1 mice were pretreated with normal saline, after 15 min with propofol 100 mg/kg IP (14). Group 2 mice were pretreated with orphenadrine 10 mg/kg /IP (15), after 15 min with propofol 100 mg/kg /IP. The mice of the third group were previously administered by orphenadrine at 20mg/kg intraperitoneal, followed by fifteen minutes administered by propofol at 100mg/kg intraperitoneal.

### **Impact of orphenadrine on the anesthesia generated by thiopental in mice**

Fifteen mice were allocation for three groups. First group were administered by normal saline intraperitoneal, followed by fifteen minutes administered by thiopental at 50mg/kg, intraperitoneal (16). The second group were administered by orphenadrine at 10mg/kg, intraperitoneal, followed by fifteen minutes administered by thiopental at 50mg/kg, intraperitoneal. The third group were administered by orphenadrine at 20mg/kg, intraperitoneal, followed by fifteen minutes administered by thiopental at 50mg/kg, intraperitoneal.

### **Impact of orphenadrine on anesthesia generated by propofol and thiopental in mice**

Fifteen mice were allocation for three groups. Group 1 mice were pretreated with normal saline, after 15 min with propofol 100 mg/kg/IP and thiopental 50 mg/kg/IP. Group 2 mice were pretreated with orphenadrine 10 mg/kg /IP, after 15 min with propofol 100 mg/kg/IP and thiopental 50 mg/kg/IP. Group 3 mice were pretreated with orphenadrine 20 mg/kg /IP, after 15 min with propofol 100 mg/kg /IP and thiopental 50 mg/kg/IP.

### **Drugs**

Orphenadrine citrate injection 30 mg/ml Teva® (USA), propofol 100 mg/10 ml DIPRIVAN® (U.K), thiopental sodium injection 1 g powder THOWELL®(INDIA). The volume of administration was 10 ml/kg/IP of body weight (3). All drugs were injected after preparing the doses in different syringes, and then the latency to onset of anesthesia was noted, which is the interval between the injection and the loss of the righting reflex of mice. The duration of anesthesia was noted, which is the interval between the loss of the righting reflex and the time it took for the mice to correct their posture, and the recovery from anesthesia, which is the interval between the time the mouse had returned to normal position and the time to resumed movement (17).

### **Statistical analysis**

One-way analysis of variance (ANOVA) followed by the Least Significant Difference test was used to assess the results statistically. Data are expressed as mean $\pm$ standard error.  $P\leq 0.05$  was chosen as the minimal degree of significance. The analysis was conducted with the statistical software SPSS 17.

## **Results**

### **Effect of orphenadrine on the anesthesia induced by propofol in mice**

As shown in table 1, the latency to onset of propofol anesthesia within approximately four minutes, the duration of anesthesia continued for half an hour through the mice return to normal position, and the recovery period was approximately twenty-five minutes, which the mice represented a return to its normal movement and behavior. When treated with orphenadrine, there was a dose-dependent decrease in latency to the onset of anesthesia and an increase in the duration of anesthesia compared with the propofol group. It was noted that the orphenadrine prolonged the anesthesia duration time. In addition, there was an increase in the recovery period in the group treated with orphenadrine 20 mg/kg compared to the propofol group.

Table 1: Impact of orphenadrine on anesthesia induced by propofol

Groups	Latency to onset (min)	Duration (min)	Recovery time (min)
Group 1	4.16±0.22 <sup>a</sup>	37.33±1.94 <sup>c</sup>	25.44±1.14 <sup>b</sup>
Group 2	3.59±0.18 <sup>a</sup>	61.49±1.43 <sup>b</sup>	19.95±0.68 <sup>c</sup>
Group 3	2.39±0.25 <sup>b</sup>	92.27±2.55 <sup>a</sup>	35.55±1.00 <sup>a</sup>

At the 5% significance level, differences between values in each column denoted by various superscript letters are significant. Values are Mean±SE.

### Effect of orphenadrine on the anesthesia induced by thiopental in mice

As shown in table 2, latency to onset of thiopental anesthesia within approximately ten minutes, the duration of anesthesia continued for a third of an hour through the mice return to normal position, and the recovery period was approximately ten minutes, which the mice represented a return to its normal movement and behavior. When treated with orphenadrine, there was a dose-dependent decrease in latency to the onset of anesthesia and an increase in the duration of anesthesia compared with the thiopental group. It was noted that the orphenadrine prolonged the anesthesia duration time. In addition, there was an increase in the recovery period in the orphenadrine group compared to that in the propofol group.

Table 2: Impact of orphenadrine on anesthesia induced by thiopental

Groups	Latency to onset (min)	Duration (min)	Recovery time (min)
Group 1	9.87±0.52 <sup>a</sup>	21.03±0.73 <sup>c</sup>	10.18±0.36 <sup>c</sup>
Group 2	4.74±0.17 <sup>b</sup>	40.58±1.01 <sup>b</sup>	20.31±0.65 <sup>b</sup>
Group 3	2.55±0.19 <sup>c</sup>	84.41±1.34 <sup>a</sup>	40.03±1.69 <sup>a</sup>

At the 5% significance level, differences between values in each column denoted by various superscript letters are significant. Values are Mean±SE.

### Effect of orphenadrine on the anesthesia induced by propofol and thiopental combination in mice

As shown in table 3, concomitant treatment with propofol and thiopental resulted in the latency to onset of anesthesia within approximately one minute, the duration of anesthesia continued for almost two hours through the mice returned to the normal position, and the recovery period was approximately half an hour, which the mice represented a return to its normal movement and behavior. When treated with orphenadrine, there was a dose-dependent decrease in the latency to the onset of anesthesia and an increase in the duration of anesthesia compared to the propofol and thiopental group. It was noted that the orphenadrine prolonged the anesthesia duration time. In addition, there

was an increase in the recovery period in the orphenadrine group compared to the propofol and thiopental group.

Table 3: Impact of orphenadrine on anesthesia induced by propofol and thiopental

Groups	Latency to onset (min)	Duration (min)	Recovery time (min)
Group 1	1.26±0.12 <sup>a</sup>	86.88±0.88 <sup>c</sup>	26.01±0.75 <sup>c</sup>
Group 2	0.93±0.06 <sup>b</sup>	127.55±1.91 <sup>b</sup>	39.28±1.88 <sup>b</sup>
Group 3	0.73±0.05 <sup>b</sup>	177.43±5.92 <sup>a</sup>	72.37±2.63 <sup>a</sup>

At the 5% significance level, differences between values in each column denoted by various superscript letters are significant. Values are Mean±SE.

## Discussion

A logical method for multimodal general anesthesia should include the following steps: administration of combinations of antinociceptive drugs, each targeting a distinct circuit in the nociceptive system; continuous monitoring of levels of antinociception and unconsciousness; expressly using the sedative effects of antinociceptive medicines to minimize the doses of hypnotic medications and inhaled anesthetics used to maintain unconsciousness; and maintaining multimodal pain control during the in-hospital postoperative period and after discharge (18,19). No anesthetic medication can supply all the constituents of general anesthesia without interfering with essential organ roles. As a result, a multi-drug method (balanced anesthesia) is used to decrease sensory, motor, sympathetic, and parasympathetic response actions, as well as distinct constituents of the anesthetic state (20-22). Therefore, this study aimed to estimate a new combination of anesthetic drugs with orphenadrine, a muscle-relaxant drug, and its effect on anesthesia indices.

Among the significant results noted in our research is that the administration of orphenadrine in doses 10 and 20 mg/kg reduced the period of onset of anesthesia and increased the induction period of anesthesia (period of surgical operation). This effect is recorded for the first time and needs further study and research to reveal the mechanism of this synergistic effect at the level of anesthesia. GABA is the core inhibitory neurotransmitter in the mammalian central nervous system (23,24). Glutamate is the primary excitatory amino acid neurotransmitter acting on NMDA and non-NMDA receptors, which play a main part in physiological processes such as memory and learning (and thus consciousness under anesthesia) and principal pain transduction mechanisms (25-27).

Propofol inhibits postsynaptic neurons by preventing GABA from dissociating from its receptors. This increases chloride entry via channels, leading to hyperpolarization of postsynaptic cell membranes and inhibition of postsynaptic neurons (28,29). Propofol also inhibits the NMDA subtype

of the glutamate receptor, probably by modulation in the channel gating (30). Propofol inhibits voltage-gated sodium currents and controls calcium influx via slow calcium channels (31,32).

Thiopental works in a manner analogous to barbiturate drugs. It acts as an agonist of (the GABA<sub>A</sub>) receptor, increasing inhibitory neurotransmission. It increases GABA binding to its receptor (an inhibitory neurotransmitter) and then increases transmembrane chloride entrances, causing hyperpolarization of the postsynaptic cell and inhibition of the postsynaptic neurons (33,34). Thiopental inhibitory activity on NMDA receptors may not be mediated via the secondary effects of the GABA<sub>A</sub> receptor agonist. These findings suggest that NMDA receptors play a role in mice's thiopental-induced anesthesia (35).

Notably, orphenadrine has no anesthetic effects; however, studies have indicated its effects on different receptors (36). Orphenadrine is a diphenylmethane analog of diphenhydramine with antimuscarinic, NMDA antagonistic, and antihistaminic characteristics to a lesser extent (37). The synergistic action of orphenadrine on propofol and thiopental anesthesia indices can be explained by its action on different receptors. Nevertheless, the hypothesis closest to explaining this synergistic effect may be through NMDA antagonism, as N-methyl-D-aspartate (NMDA) receptors are essential in the nervous system's excitatory neurotransmission. Some general anesthetics preferentially block them, so they have been implicated in mediating their effects (38). Hypnotic effects of ketamine occur by blocking NMDA receptors in nervous tissue (39). Blocking NMDA receptors is related to the immobilization effect of inhalational anesthetics (40,41).

## Conclusion

It could be concluded that pretreatment with orphenadrine affects anesthesia indices for both propofol and thiopental alone or together. These results provide a foundation for further research and investigation. Orphenadrine can be used in clinical studies on different animals to investigate its safety and its possible use in various surgical procedures.

## Acknowledgment

The author is grateful to the College of Veterinary Medicine, University of Mosul, for providing the resources necessary to complete this study.

## Conflict of interest

No conflict of interest.

## References

1. Lin S, Neelankavil J, Wang Y. Cardioprotective effect of anesthetics: Translating science to practice. *J Cardiothorac Vasc Anesth.* 2021;35(3):730-740. DOI: [10.1053/j.jvca.2020.09.113](https://doi.org/10.1053/j.jvca.2020.09.113)

2. Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. *Nature.* 1994;367(6464):607-614. DOI: [10.1038/367607a0](https://doi.org/10.1038/367607a0)
3. Navarro KL, Huss M, Smith JC, Sharp P, Marx JO, Pacharinsak C. Mouse anesthesia: The art and science. *Inst Lab Anim Res J.* 2021;62(1-2):238-273. DOI: [10.1093/ilar/ilab016](https://doi.org/10.1093/ilar/ilab016)
4. Lavand'homme P. Opioid-free anaesthesia: Pro: Damned if you don't use opioids during surgery. *Eur J Anaesthesiol.* 2019;36(4):247-249. DOI: [10.1097/EJA.0000000000000966](https://doi.org/10.1097/EJA.0000000000000966)
5. Mougeot R, Jubault P, Legros J, Poisson T. Continuous flow synthesis of propofol. *Mol.* 2021;26(23):7183. DOI: [10.3390/molecules26237183](https://doi.org/10.3390/molecules26237183)
6. Lee JH. Anesthesia for ambulatory surgery. *Korean J Anesthesiol.* 2017;70(4):398-406. DOI: [10.4097/kjae.2017.70.4.398](https://doi.org/10.4097/kjae.2017.70.4.398)
7. Sneyd JR, Gambus PL, Rigby-Jones AE. Current status of perioperative hypnotics, role of benzodiazepines, and the case for remimazolam: A narrative review. *Br J Anaesth.* 2021;127(1):41-55. DOI: [10.1016/j.bja.2021.03.028](https://doi.org/10.1016/j.bja.2021.03.028)
8. Pandit JJ. Intravenous anaesthetic agents. *Anaesth Intensive Care Med.* 2011;12(4):144-150. DOI: [10.1016/j.mpaic.2010.12.010](https://doi.org/10.1016/j.mpaic.2010.12.010)
9. Wolfe JW, Ehrenfeld JM. Pharmacology of intravenous anesthetic agents. In: Ehrenfeld JM, Urman RD, Segal BS, editors. *Anesthesia student survival guide: A case-based approach.* USA: Springer; 2022. 57-75 p. DOI: [10.1007/978-3-030-98675-9\\_4](https://doi.org/10.1007/978-3-030-98675-9_4)
10. Balestrino R, Schapira AV. Parkinson disease. *Eur J Neurol.* 2020;27(1):27-42. DOI: [10.1111/ene.14108](https://doi.org/10.1111/ene.14108)
11. Steyn L. Focus on: Orphenadrine citrate as a muscle relaxant. *South African Fam Pract.* 2019;61(3):6-8. DOI: [10.4102/safp.v61i3.4975](https://doi.org/10.4102/safp.v61i3.4975)
12. Köse Ç, Shahzadi A, Akkan AG, Özyazgan S. The effect of orphenadrine on rewarding property of morphine-induced conditioned place preference. *Cerrahpaşa Med J.* 2020;44(2):80-85. DOI: [10.5152/cjm.2020.20003](https://doi.org/10.5152/cjm.2020.20003)
13. Ushkalova EA, Zyryanov SK, Zatulochina KE. The fixed combination of diclofenac and orphenadrine in the treatment of acute pain syndromes. *Neurol Neuropsychiatry Psychosom.* 2020;12(1):100-104. DOI: [10.14412/2074-2711-2020-100-104](https://doi.org/10.14412/2074-2711-2020-100-104)
14. Alves HC, Valentim AM, Olsson IAS, Antunes LM. Intraperitoneal propofol and propofol fentanyl, sufentanil and remifentanil combinations for mouse anaesthesia. *Lab Anim.* 2007;41(3):329-336. DOI: [10.1258/002367707781282767](https://doi.org/10.1258/002367707781282767)
15. Hunskaar S, Berge O, Hole K. Orphenadrine citrate increases and prolongs the antinociceptive effects of paracetamol in mice. *Acta Pharmacol Toxicol.* 1986;59(1):53-59. DOI: [10.1111/j.1600-0773.1986.tb00134.x](https://doi.org/10.1111/j.1600-0773.1986.tb00134.x)
16. Ge ZJ, Zhang LC, Zeng YM, Da TJ, Wang JK, Cui GX, Tan YF, Zhao YP, Liu GJ. Involvement of NMDA receptors in thiopental-induced loss of righting reflex, antinociception and anticonvulsion effects in mice. *Pharmacol.* 2007;80(2-3):127-33. DOI: [10.1159/000103252](https://doi.org/10.1159/000103252)
17. Alves HC, da Silva AM, Olsson IAS, Orden JG, Antunes LM. Anesthesia with intraperitoneal propofol, medetomidine, and fentanyl in rats. *J Am Assoc Lab Anim Sci.* 2010;49(4):454-459. [\[available at\]](#)
18. Brown EN, Pavone KJ, Naranjo M. Multimodal general anesthesia: Theory and practice. *Anesth Analg.* 2018;127(5):1246. DOI: [10.1213/ANE.0000000000003668](https://doi.org/10.1213/ANE.0000000000003668)
19. Mahmood MB. A Comparison between ketamine-xylazine and ketamine-midazolam or all of them to induce balance anesthesia in rabbits. *Iraqi J Vet Sci.* 2022;36(2):499-506. DOI: [10.33899/ijvs.2021.130618.1852](https://doi.org/10.33899/ijvs.2021.130618.1852)
20. Potliya S, Kumar A, Kumar S, Singh S, Kumar S. Evaluation of efficacy and safety of glycopyrrolate-xylazine-propofol anesthesia in buffalo calves. *Vet World.* 2015;8(3):251. DOI: [10.14202/vetworld.2015.251-256](https://doi.org/10.14202/vetworld.2015.251-256)
21. Naser AS, Albadrany YM. The neurobehavioral effects of flumazenil in chicks. *Iraqi J Vet Sci.* 2021;35(4):783-8. DOI: [10.33899/ijvs.2020.128443.1577](https://doi.org/10.33899/ijvs.2020.128443.1577)
22. Mousa YJ, Mahmood MB, Mohammed ZT. Simultaneous determination of pethidine pharmacokinetics in rats: The impact of tramadol coadministration. *Iraqi J Vet Sci.* 2023;37(1):261-7. DOI: [10.33899/ijvs.2022.133824.2307](https://doi.org/10.33899/ijvs.2022.133824.2307)

23. Naser AS, Albadrany Y, Shaaban KA. Isobolographic analysis of analgesic interactions of silymarin with ketamine in mice. J Hellenic Vet Med Soc. 2020;71(2):2171-8. DOI: [10.12681/jhvms.23653](https://doi.org/10.12681/jhvms.23653)
24. Alberifki NM, Naser AS. Flurbiprofen: Determination of safety profile, analgesic effect, and interaction with lipoic acid in murine. Iraqi J Vet Sci. 2023;37(2):447-52. DOI: [10.33899/ijvs.2023.136615.2599](https://doi.org/10.33899/ijvs.2023.136615.2599)
25. Hudspith MJ. Glutamate: A role in normal brain function, anaesthesia, analgesia and CNS injury. Br J Anaesth. 1997;78(6):731-747. DOI: [10.1093/bja/78.6.731](https://doi.org/10.1093/bja/78.6.731)
26. Mohammed QM, Albadrany YM. Pregabalin potentiates the analgesic effect of tramadol, diclofenac and paracetamol in chicks: Isobolographic analysis. Iraqi J Vet Sci. 2022;36(4):931-7. DOI: [10.33899/ijvs.2022.132586.2108](https://doi.org/10.33899/ijvs.2022.132586.2108)
27. Fadel MA, Mustafa KA. The anti-inflammatory effect of allopurinol and diclofenac in chicks' model. Iraqi J Vet Sci. 2023;37(3):547-553. DOI: [10.33899/ijvs.2023.138108.2769](https://doi.org/10.33899/ijvs.2023.138108.2769)
28. Platholi J, Hemmings Jr HC. Effects of general anesthetics on synaptic transmission and plasticity. Curr Neuropharmacol. 2022;20(1):27. DOI: [10.2174/1570159X19666210803105232](https://doi.org/10.2174/1570159X19666210803105232)
29. Lu M, Liu J, Wu X, Zhang Z. Ciprofol: A novel alternative to propofol in clinical intravenous anesthesia?. BioMed Res Int. 2023;19(2023):1-12. DOI: [10.1155/2023/7443226](https://doi.org/10.1155/2023/7443226)
30. Marik PE. Propofol: Therapeutic indications and side-effects. Curr Pharm Des. 2004;10(29):3639-3649. DOI: [10.2174/1381612043382846](https://doi.org/10.2174/1381612043382846)
31. Ouyang W, Wang G, Hemmings HC. Isoflurane and propofol inhibit voltage-gated sodium channels in isolated rat neurohypophysial nerve terminals. Mol Pharmacol. 2003;64(2):373-381. DOI: [10.1124/mol.64.2.373](https://doi.org/10.1124/mol.64.2.373)
32. Brohan J, Goudra BG. The role of GABA receptor agonists in anesthesia and sedation. CNS Drugs. 2017;31:845-856. DOI: [10.1007/s40263-017-0463-7](https://doi.org/10.1007/s40263-017-0463-7)
33. Kojima A, Fukushima Y, Matsuura H. Prediction of anesthetic torsadogenicity using a human ventricular cell model. J Anesth. 2023;31:1-5. DOI: [10.1007/s00540-023-03238-9](https://doi.org/10.1007/s00540-023-03238-9)
34. Kavakbasi E, Stoelck A, Wagner NM, Baune BT. Differences in cognitive adverse effects and seizure parameters between thiopental and propofol anesthesia for electroconvulsive therapy. J ECT. 2023;39(2):97-101. DOI: [10.1097/YCT.0000000000000893](https://doi.org/10.1097/YCT.0000000000000893)
35. Ge ZJ, Zhang LC, Zeng YM, Da TJ, Wang JK, Cui GX, Tan YF, Zhao YP, Liu GJ. Involvement of NMDA receptors in thiopental-induced loss of righting reflex, antinociception and anticonvulsion effects in mice. Pharmacol. 2007;80(2-3):127-133. DOI: [10.1159/000103252](https://doi.org/10.1159/000103252)
36. Zeiner S, Haider T, Zotti O, Thüringer K, Höbart P, Kimberger O, Knolle E. Intravenous diclofenac and orphenadrine for the treatment of postoperative pain after remifentanyl-based anesthesia: A double-blinded, randomized, placebo-controlled study. Wien Klin Wochenschr. 2023;135(3-4):67-74. DOI: [10.1007/s00508-022-02131-x](https://doi.org/10.1007/s00508-022-02131-x)
37. Czuczwar M, Cieszczyk J, Czuczwar K, Kiś J, Saran T, Turski WA. Influence of orphenadrine upon the protective activity of various antiepileptics in the maximal electroshock-induced convulsions in mice. Pharmacol Rep. 2009;61(4):732-736. DOI: [10.1016/S1734-1140\(09\)70127-6](https://doi.org/10.1016/S1734-1140(09)70127-6)
38. Petrenko AB, Yamakura T, Sakimura K, Baba H. Defining the role of NMDA receptors in anesthesia: Are we there yet?. Eur J Pharmacol. 2014;723:29-37. DOI: [10.1016/j.ejphar.2013.11.039](https://doi.org/10.1016/j.ejphar.2013.11.039)
39. Mousa YJ, Alzubaidy MH, Amin SM. Age-related anesthetic effect of ketamine in the chickens. Iraqi J Vet Sci. 2021;6(4):12-20. DOI: [10.33899/ijvs.2020.127100.1458](https://doi.org/10.33899/ijvs.2020.127100.1458)
40. Hudson AE, Herold KF, Hemmings Jr HC. Pharmacology of inhaled anesthetics. In: Hemmings HC, Egan TD, editors. Pharmacology and physiology for anesthesia. USA: Elsevier; 2019. 217-240 p. DOI: [10.1016/B978-0-323-48110-6.00011-9](https://doi.org/10.1016/B978-0-323-48110-6.00011-9)
41. Mukai A, Irifune M, Shimizu Y, Doi M, Kikuchi Y, Katayama S, Oue K, Yoshida M, Ago Y, Okada Y, Morioka N. N-methyl-D-aspartate receptors and glycinergic transmission, respectively, mediate muscle relaxation and immobility of pentobarbital in mice. Neurosci Lett. 2023;802:137175. DOI: [10.1016/j.neulet.2023.137175](https://doi.org/10.1016/j.neulet.2023.137175)

## الكشف عن التأثيرات المحتملة للأورفينادرين على التخدير بالبروبوفول و/أو الثايوبنتال في الفئران

ياسر محمداين البدراني و أحمد صلاح ناصر و خالد احمد شعبان

فرع الفسلجة والكيمياء الحياتية والأدوية، كلية الطب البيطري جامعة الموصل، الموصل، العراق

### الخلاصة

الأورفينادرين هو دواء مضاد للكولين يستخدم سريريا كمرخي للعضلات. ويعمل على العديد من المستقبلات بما في ذلك مستقبلات المسكارين والهستامين ومستقبلات NMDA. هدفت هذه الدراسة إلى تقييم تأثير المعاملة المسبقة بالأورفينادرين على مؤشرات التخدير لعقارين مهمين للتخدير بالحقن في الفئران. أجريت ثلاث تجارب مع ١٥ فأر لكل تجربة. في جميع التجارب تم استخدام الأورفينادرين بالجرع (١٠ و ٢٠ ملغم/كغم/في الخلب) كدواء معاملة مسبق. تم استخدام البروبوفول (١٠٠ ملغم/كغم/في الخلب)، والثايوبنتال (٥٠ ملغم/كغم/في الخلب)، وكلا الدوائيين سويا في التجارب الأولى والثانية والثالثة على التوالي. تم تسجيل مؤشرات التخدير، المتمثلة في بداية التخدير، ومدة التخدير، والتعافي من التخدير. أظهرت النتائج الرئيسية للاستخدام الأورفينادرين كعلاج مسبق انخفاضاً يعتمد على الجرعة في بداية التخدير وزيادة في مدة التخدير مقارنة بمجموعات السيطرة في كل التجارب. نستنتج أن للأورفينادرين تأثير على مؤشرات التخدير، والتي تم تسجيلها لأول مرة، مما يضع الأساس لمزيد من الدراسات وإمكانية استخدامه كعلاج مرافق في التخدير.